Investor Presentaiton slide image

Investor Presentaiton

III Sustainability of Growth and Margin Profile Sustainability of Revenue Growth A Market Volume Drives B Company Specific Volume Drivers Population Growth CAGR (19E-23E): 2.0 % 0.9 % Egyptian population is projected to grow at higher CAGR than the Global average Continuously enhancing market share in both retail and non-retail market segment Average Selling Price Drivers Constant improvement in average selling prices Supply side mechanism for price adjustment through migrating to higher price points Recovering Consumer Expenditure GDP per capita in Egypt 3.0 (USD 000's): Pick up in macro- economic standard 2014 12.6% Consumer Expenditure CAGR (19E-24E): +1.5% ISP Market Share +x% ISP Market Share Gains II Prices remain extremely low with further adjustments expected to take place Among the highest 2015 consumer emerging 14.1% 2.0 2.6 3.1 10.6 markets expected to grow % +2.3% 7.3% Average Selling Price (ASP) Evolution 4.2% 4.0% 2016 16.4% +1.6% 2016 2017 2018 2019 2017 18.0% Unjustifiably low pharmaceutical sales per capital 322 235 +2.0% 110 99 95 66 51 28 15 2018 20.0% Egyptian Pharmaceutical Market Size (Volume in mn) CAGR: 3.9% 2019 21.3% +10% 3,490 2,891 3,035 3,172 2,849 3,210 2014 2015 2016 2017 2018 2019 +5.5% 16.5 +17.0% 19.3 +34.7% 26.0 4.5 +10.0% +10.9% 28.6 31.7 1.3 15.3 21.5 18 +1.3% Average increase of 1.5% per year in market share during the last 5 years 2014 2015 2016 2017 2018 2019 Normalized ASP Price waves Effect Ibnsina Pharma Revenue (EGP mn) 3,357 4,302 5,439 CAGR: 31% 7,372 Constant double digit growth for the upcoming 5 years is achievable in light of the current market and company dynamics 9,818 13,678 16,941 2013 2014 2015 2016 2017 2018 2019 E 2020E 2021 E 2022 E 2023 E ibnsinapharma Source: EIU, Company Management 28
View entire presentation